Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1153-1165

  Bellone, Graziella ^a   Gramigni, Claudia ^a   Vizio, Barbara ^a   Mauri, Francesco A ^b   Prati, Adriana ^a   Solerio, Dino ^a   Dughera, Luca ^c   Ruffini, Enrico ^a   Gasparri, Guido ^a   Camandona, Michele ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Colon adenoma; Colorectal carcinoma; Endoglin; Receptors; TGF

Indexed keywords

ENDOGLIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; COLON ADENOMA; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DYSPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 77957860128     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000767     Document Type: Article

References (98)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics. CA Cancer J Clin 56: 106-130, 2006.
2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
3. Cho KR and Vogelstein B: Genetic alterations in the adenomacarcinoma sequence. Cancer 70: 1727-1731, 1992.
4. Salgado R, Benoy I, Vermeulen P, van Dam P, van Marck E and Dirix L: Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. Angiogenesis 7: 29-32, 2004. (Pubitemid 39127768)
5. Kos M and Dabrowski A: Tumour's angiogenesis - the function of VEGF and bFGF in colorectal cancer. Ann Univ Mariae Curie Sklodowska Med 57: 556-561, 2002.
6. Pardali E and ten Dijke P: Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci 14: 4848-4861, 2009.
7. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989. (Pubitemid 19115892)
8. Barnhill RL, Fandrey K, Levy MA, Mihm MCn Jr and Hyman B: Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67: 331-337, 1992.
9. Smith-McCune KK and Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54: 800-804, 1994.
10. Bossi P, Viale G, Lee AK, Alfano R, Coggi G and Bosari S: Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55: 5049-5053, 1995.
11. Fontanini G, Calcinai A, Boldrini L, et al: Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 6: 813-817, 1999.
12. Kitadai Y, Onogawa S, Kuwai T, et al: Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma. Oncol Rep 11: 315-319, 2004.
13. Bamberger ES and Perrett CW: Angiogenesis in benign, pre-malignant and malignant vulvar lesions. Anticancer Res 22: 3853-3865, 2002. (Pubitemid 36134406)
14. Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ and Reed MW: The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut 56: 1426-1432, 2007.
15. Elliott RL and Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol 23: 2078-2093, 2005. (Pubitemid 46211385)
16. Massagué J: TGFbeta in cancer. Cell 134: 215-230, 2008.
17. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, Dohi S and Uematsu T: Involvement of p38 MAP kinase in TGF-β-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 82: 591-598, 2001. (Pubitemid 32720675)
18. Goumans MJ and Mummery C: Functional analysis of the TGF receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 44: 253-265, 2000.
19. Jakowlew SB: Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457, 2006. (Pubitemid 44922360)
20. Massagué J: TGF-β signal transduction. Annu Rev Biochem 67: 753-791, 1998.
21. Massagué J and Gomis RR: The logic of TGFβ signalling. FEBS Lett 580: 2811-2820, 2006.
22. Shi Y and Massagué J: Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 13: 685-700, 2003. (Pubitemid 36724933)
23. Barbara NP, Wrana JL and Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594, 1999. (Pubitemid 129535212)
24. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P and Miyazono K: Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001, 1994.
25. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A and Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 277: 29197-29209, 2002.
26. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massagué J and Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
27. Miller DW, GraulichW, Karges B, et al: Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572, 1999.
28. Lebrin F, Goumans MJ and Jonker L: Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028, 2004.
29. Burrows FJ, Derbyshire EJ, Tazzari PL, et al: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
30. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14: 1931-1937, 2008.
31. Astler VB and Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846-852, 1954.
32. Ramakers C, Ruijter JM, Deprez RH and Moorman AF: Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62-66, 2003. (Pubitemid 36263221)
33. Rasmussen R: Quantification on the LightCycler. In: Rapid Cycle Real-time PCR, Methods and Applications. Meuer S, Wittwer C and Nakagawara K (eds.) Springer Press, Heidelberg, pp21-34, 2001.
34. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
35. Haruta Y and Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 83: 7898-7902, 1986. (Pubitemid 17183950)
36. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991. (Pubitemid 24058195)
37. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
38. Nakagawa S and Kitoh T: Measurement of KIT ligand/stem cell factor: clinical and biochemical significance. Curr Opin Hematol 7: 133-142, 2000. (Pubitemid 30213145)
39. Konishi F and Morson BC: Pathology of colorectal adenomas: a colonoscopic survey. Clin Pathol 35: 830-841, 1982. (Pubitemid 12048799)
40. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
41. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M and Abe T: Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 31: S109-S113, 2002. (Pubitemid 34118625)
42. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T and Tokunaga O: Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch 448: 127-134, 2006. (Pubitemid 43237877)
43. Hanahan D and Folkman J: Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
44. Jin Y, Tipoe GL, White FH and Yang L: A quantitative investigation of immunocytochemically stained blood vessels in normal, benign, premalignant and malignant human oral cheek epithelium. Virchows Arch 427: 145-151, 1995.
45. Meert A-P, Feoli F, Martin B, Ninane V and Sculier J-P: Angiogenesis in preinvasive, early invasive bronchial lesions and micropapillomatosis and correlation with EGFR expression. Histopathology 50: 311-317, 2007. (Pubitemid 46169415)
46. Van der Kerkhof PC, Rulo HF, van Pelt JP, van Vlijmen-Willems IM and De Jong EM: Expression of endoglin in the transition between psoriatic uninvolved and involved skin. Acta Derm Venereol 78: 19-21, 1998.
47. Auvinen MI, Sihvo EI, Ruohtula T, et al: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20: 2971-2979, 2002.
48. Li C, Gardy R, Seon BK, et al: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88: 1424-1431, 2003.
49. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D and Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17: 197-203, 2004. (Pubitemid 41656516)
50. Romani AA, Borghetti AF, Del Rio P, Sianesi M and Soliani P: The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 93: 446-455, 2006. (Pubitemid 44651267)
51. Wikström P, Lissbrant IF, Stattin P, Egevad L and Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-275, 2002. (Pubitemid 34556377)
52. Bodey B, Bodey B, Siegel SE and Kaiser HE: Overexpression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anticancer Res 18: 3621-3628, 1998. (Pubitemid 28546500)
53. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM and Bundred N: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861, 1999. (Pubitemid 29086739)
54. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B and Rasmuson T: Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 97: 706-710, 2006. (Pubitemid 43383499)
55. Saad RS, El-Gohary Y, Memari E, Liu YL and Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 36: 955-961, 2005. (Pubitemid 41253380)
56. Bellone G, Solerio D, Chiusa L, et al: Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent non-tumorous esophagus as prognostic predictor of recurrence. Ann Surg Oncol 14: 3232-3242, 2007.
57. Kyzas PA, Agnantis NJ and Stefanou D: Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 448: 768-775, 2006. (Pubitemid 43824434)
58. + microvessel density in HNSCC patient outcome. Oral Oncol 41: 147-155, 2005.
59. Saad RS, Jasnosz KM, Tung MY and Silverman JF: Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 22: 248-253, 2003. (Pubitemid 36750406)
60. Tanaka F, Otake Y and Yanagihara K: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7: 3410-3415, 2001.
61. Bellón T, Corbí A, Lastres P, et al: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993.
62. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H and Seon BK: Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 7: 524-532, 2001. (Pubitemid 32707974)
63. Mysliwiec P, Pawlak K, Kukliñski A and Kedra B: Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients. Folia Histochem Cytobiol 47: 231-236, 2009.
64. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N and Kumar S: Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89: 122-126, 2000. (Pubitemid 30185919)
65. Fonsatti E, Altomonte M, Nicotra MR, Natali PG and Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22: 6557-6563, 2003. (Pubitemid 37372335)
66. ten Dijke P, Goumans MJ and Pardali E: Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89, 2008.
67. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G and Egido J: TGF-β signaling in vascular fibrosis. Cardiovasc Res 74: 196-206, 2007.
68. Bernabeu C, Lopez-Novoa JM and Quintanilla M: The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792: 954-973, 2009.
69. Akhurst RJ, Lehnert SA, Faissner A and Duffie E: TGFβ in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108: 645-656, 1990. (Pubitemid 20140388)
70. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM and Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94: 239-246, 2006. (Pubitemid 43151542)
71. Langenskiöld M, Holmdahl L, Falk P, Angenete E and Ivarsson ML: Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 97: 409-415, 2008. (Pubitemid 351466383)
72. Bellone G, Carbone A, Tibaudi D, et al: Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer 37: 224-233, 2001.
73. Von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR and Sarbia M: Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45: 786-794, 2006. (Pubitemid 44484989)
74. Suda A, Saito N, Seshimo A, Kameoka S and Kobayashi M: Examination of transforming growth factor beta1 expression in the serum and tumor tissue of gastric cancer. Int Surg 94: 182-188, 2009.
75. Nio Y, Omori H, Hashimoto K, et al: Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res 25: 3523-3529, 2005.
76. Dong ZZ, Yao DF, Yao M, et al: Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 7: 288-295, 2008.
77. Kong F, Jirtle RL, Huang DH, Clough RW and Anscher MS: Plasma TGF-β1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer 86: 1712-1719, 1999. (Pubitemid 29513039)
78. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L and Di Silverio F: Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22: 1-10, 2000. (Pubitemid 30106500)
79. Bruna A, Darken RS, Rojo F, et al: High TGF-β-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160, 2007.
80. Moretti S, Pinzi C, Berti E, et al: In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7: 313-321, 1997.
81. Piek E and Roberts AB: Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 83: 1-54, 2001. (Pubitemid 32959260)
82. Roberts AB and Wakefield LM: The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623, 2003. (Pubitemid 36899145)
83. Wang J, Sun L, Myeroff L, et al: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270: 22044-22049, 1995.
84. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14: 55-64, 2000. (Pubitemid 30051523)
85. Lastres P, Letamendia A, Zhang H, et al: Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121, 1996.
86. Sánchez-Elsner T, Botella LM, Velasco B, Langa C and Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 277: 43799-43808, 2002. (Pubitemid 36157800)
87. Dassoulas K, Gazouli M, Theodoropoulos G, et al: Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol 136: 703-708, 2010.
88. Zvrko E, Mikic A, Vuckovic L, Djukic V and Knezevic M: Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma. Otolaryngol Head Neck Surg 141: 478-483, 2009.
89. Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H and Miyazaki M: Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 37: 275-281, 2008.
90. Barresi V, Cerasoli S, Vitarelli E and Tuccari G: Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114: 147-156, 2007. (Pubitemid 47103525)
91. El-Gohary YM, Silverman JF and Olson PR: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127: 572-579, 2007.
92. Dales JP, Garcia S, Andrac L, et al: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 24: 1197-1204, 2004.
93. Koumoundourou D, Kassimatis T, Zolota V, et al: Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. Anticancer Res 27: 2613-2620, 2007.
94. Hazelbag S, Kenter GG, Gorter A and Fleuren GJ: Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 112: 1020-1028, 2004. (Pubitemid 39507009)
95. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O and Nikolic-Vukosavljevic D: Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39: 454-461, 2003.
96. Logullo AF, Nonogaki S, Miguel RE, et al: Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med 32: 139-145, 2003.
97. Robson H, Anderson E, James RD and Schofield PF: Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74: 753-758, 1996. (Pubitemid 26300767)
98. Wagner AD, Arnold D, Grothey AA, Haerting J and Unverzagt S: Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 8: 1-78, 2009. (Pubitemid 351805141)